The minutes of the November 19, 2024, FDA joint advisory committee meeting have been posted. As previously reported, this meeting was called to discuss reevaluation of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) and possible changes to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of clozapine. With the joint FDA advisory committees overwhelmingly voting to eliminate the risk evaluation and mitigation strategy (REMS), AAPP has continued its advocacy on the REMS in conjunction with partners such as the American Psychiatric Association, Angry Moms, the Schizophrenia and Psychosis Alliance, and more. AAPP has earmarked March 18 at 10 AM central time for a webinar to update members on our advocacy and to discuss practice implications should the REMS be eliminated. More information and registration forthcoming!